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SUMMARY  
Mitochondria  are  essential  for  numerous  cellular  processes,  yet  hundreds  of  their  proteins  lack  
robust   functional   annotation.   To   reveal   new   functions   for   these   proteins   (termed   MXPs)   we  
assessed   condition-­specific   protein-­protein   interactions   for   50   select   MXPs   using   affinity  
enrichment   mass   spectrometry.   Our   data   connect   MXPs   to   diverse  mitochondrial   processes,  
including  multiple   aspects   of   respiratory   chain   function.  Building  upon   these  observations,  we  
validated  C17orf89  as  a  complex  I  (CI)  assembly  factor.  Disruption  of  C17orf89  markedly  reduced  
CI   activity,   and   its   depletion   is   found   in   an   unresolved   case   of   CI   deficiency.   We   likewise  
discovered  that  LYRM5  interacts  with  and  deflavinates  the  electron  transferring  flavoprotein  that  
shuttles  electrons  to  coenzyme  Q  (CoQ).  Finally,  we  identified  a  dynamic  human  CoQ  biosynthetic  
complex   involving   multiple   MXPs   whose   topology   we   map   using   purified   components.  
Collectively,  our  data   lend  new  mechanistic   insight   into   respiratory  chain-­related  activities  and  







Mitochondria  are  centers  of  metabolism  for  nearly  all  eukaryotic  cells.  Once  considered  to  
be  mere  sites  of  ATP  generation,   it   is  now  appreciated   that  mitochondria  participate   in  a  wide  
range  of  essential  functions  related  to  cellular  metabolism,  signaling,  and  programmed  cell  death  
(Pagliarini   and   Rutter,   2013).   Consistently,   large-­scale   proteomics-­   and   computation-­based  
efforts   during   the   past   decade   have   revealed   that   the  mitochondrial   proteome   is  much  more  
extensive   than   once   thought,   and   dysfunction   of   these   organelles   is   now   associated   with  
hundreds  of  inborn  errors  of  metabolism  and  common  diseases  (Koopman  et  al.,  2012;;  Nunnari  
and  Suomalainen,  2012).  
Despite  our  advanced  cataloging  of   the  mammalian  mitochondrial  proteome,   functional  
characterization  of  these  proteins  is  far  from  complete  (Calvo  et  al.,  2016;;  Pagliarini  et  al.,  2008).  
This   gap   in   knowledge   has   limited   our   understanding   of   basic  mitochondrial   biology   and   has  
obscured  the  nature  and  cause  of  many  mitochondrial  diseases.  For  instance,  many  patients  with  
biochemically-­established  mitochondrial  disease  lack  mutations  in  known  mitochondrial  disease  
genes,  implying  the  existence  of  unidentified  proteins  whose  proper  function  is  necessary  for  the  
affected  process  (Calvo  et  al.,  2010;;  Haack  et  al.,  2011).  Alternatively,  other  diseases  arise  from  
mutations  in  mitochondrial  proteins  with  no  known  function,  making  it  difficult  to  interrogate  the  
molecular  mechanism  of  the  disease.  
Protein-­protein   interactions   (PPIs)   can   provide   powerful   insight   into   protein   function.  
Recent  advancements  in  affinity  enrichment  mass  spectrometry  (AE-­MS)  (Hein  et  al.,  2015;;  Hosp  
et  al.,  2015;;  Huttlin  et  al.,  2015;;  Keilhauer  et  al.,  2015)  have  improved  the  ability   to  accurately  
detect  PPIs,  enabling  researchers  to  overcome  the  systematic  bias  against  poorly  characterized  
proteins  inherent  in  many  large-­scale  “interactome”  analyses  (Sahni  et  al.,  2015).  With  AE-­MS,  a  
protein  of  interest  (i.e.,  the  bait)  is  enriched  from  a  sample;;  it,  along  with  any  co-­enriching  proteins,  
is  then  analyzed  by  mass  spectrometry  (MS).  In  this  process,  the  majority  of  captured  proteins  
are  typically  not  meaningful  interactors  of  the  bait.  To  sort  the  so-­called  wheat  from  the  chaff,  the  
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AE-­MS  approach  combines  the  analyses  of  multiple  baits  with  a  robust  quantitative  MS  platform  
and   a   scoring   algorithm   to   differentiate   between   informative   interactions   and   nonspecific  
background  co-­enrichment.  
In  this  study,  we  began  by  curating  a  list  of  proteins  from  the  mitochondrial  proteome  that  
lack  significant   functional  annotation,  which  we  call  mitochondrial  uncharacterized   (x)  proteins  
(MXPs).  Using  stringent  criteria,  we  conservatively  estimate  there  to  be  228  MXPs  in  humans,  
including  more   than  25   that  have  been  associated  with  human  diseases.  We  then  designed  a  
robust  AE-­MS  strategy  to  define  an  extensive  cell  type-­  and  condition-­specific  interactome  of  50  
select   MXPs,   enabling   us   to   propose   new   functions   and   disease   associations   for   these  
uncharacterized  proteins.  
Informed   by   our   large-­scale   AE-­MS   analyses,   we   conducted   extensive   in   vitro  
biochemistry  and  cell  biology  experiments  that  validated  roles  for  MXPs  in  various  aspects  of  the  
mitochondrial   respiratory   chain.  We   establish   C17orf89   as   a   complex   I   (CI)   assembly   factor,  
whose  silencing  markedly  impairs  CI  activity,  and  whose  depletion  is  found  in  an  unresolved  case  
of  isolated  CI  deficiency.  We  also  establish  LYRM5  as  a  “deflavinase”  that  directly  regulates  the  
electron  transferring  flavoprotein  (ETF),  and  identify  a  dynamic  human  coenzyme  Q  biosynthetic  
complex  that  includes  multiple  MXPs.  We  propose  functions  for  a  variety  of  other  MXPs  and  make  




At  least  twenty  percent  of  the  mitochondrial  proteome  lacks  functional  annotation  
Previous  analyses  have  suggested  that  much  of  the  mitochondrial  proteome  is  uncharacterized  
(Pagliarini   et   al.,   2008;;  Pagliarini   and  Rutter,   2013).   To   capture   an   up-­to-­date   assessment   of  
mitochondrial  proteins  and  their  functions,  we  combined  the  recently  updated  MitoCarta  2.0  list  
(Calvo  et  al.,  2016)  with  additional  literature  sources  to  generate  a  MitoCarta+  list  of  1,166  human  
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proteins  with  validated  mitochondrial  localization  (Table  S1).  Next,  we  annotated  these  proteins  
based   on   the   integration   of   online   databases   and   analysis   of   the   current   literature   (see  
Experimental  Procedures).  Our  data   indicate   that   at   least  228  mitochondrial   proteins  have  no  
known,  or  poorly  established,  biochemical  function,  and  that  an  additional  26  proteins  with  dual  
localization  to  the  mitochondrion  and  another  cellular  compartment  do  not  have  clear  roles  within  
the  mitochondrion.  These  MXPs  constitute  approximately  20%  of  the  mammalian  mitochondrial  
proteome,   and   include   many   proteins   associated   with   human   disease   (Table   S1,   and   see  
Supplemental  Experimental  Procedures).  
  
Overall  experimental  strategy    
To   begin   characterizing   the   functions   of   MXPs,   we   elected   to   establish   MXP-­specific  
interactions   via   affinity   enrichment-­mass   spectrometry   (AE-­MS)—an   approach   proven   to   be  
capable  of  efficiently  connecting  uncharacterized  proteins   to  known  pathways  (Figure  1A).  We  
prioritized   an   initial   set   of   50   MXPs   (Table   S1)   based   on   disease-­relevance,   evolutionary  
conservation,  and  confirmed  localization  to  mitochondria  when  possessing  a  C-­terminal  FLAG-­
tag  (Figure  1B,  S1).  We  supplemented  these  bait  proteins  with  27  mitochondrial  proteins  of  known  
function   (Table   S1),   and   a   variant   of   green   fluorescent   protein   harboring   an   N-­terminal  
mitochondrial  localization  sequence  (MLS-­GFP-­FLAG).  We  performed  our  interaction  analyses  in  
two   cell   lines   (HEK293   and   HepG2)   grown   in   both   glucose-­   and   galactose-­based   media  
conditions.   Galactose   is   known   to   increase   oxygen   consumption   and   dependence   on  
mitochondrial   respiratory   chain   function,   which   we   observed   in   both   lines   (Figure   1C).   We  
collected   three   replicates   (i.e.,   distinct   cell   transfections)   of   each   condition   for   a   total   of   12  
analyses  per  bait  protein.  
Following   anti-­FLAG   immunoaffinity   enrichment,   protein   eluent   was   analyzed   using  
nanoflow  liquid  chromatography  coupled  to  high  resolution  mass  spectrometry  (quadrupole  linear  
ion   trap-­Orbitrap   hybrid,   nLC-­MS/MS).   Analysis   of   these   78   unique   baits   required   936   nLC-­
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MS/MS   experiments   that   generated   20   million   MS/MS   spectra,   identified   5   million   unique  
peptides,  and  resulted  in  the  discovery  of  10,000  unique  proteins.  On  average,  each  nLC-­MS/MS  
experiment  detected  ~  1,000  unique  proteins;;  however,  each  bait  likely  has  far  fewer  bona  fide  
interactions.  To  help  distinguish  genuine  interactions  from  background,  we  utilized  CompPASS,  
a   known   and   validated   algorithmic   approach   to   highlighting   high-­confidence   interactions   and  
removing  non-­specific  binders  (Sowa  et  al.,  2009),  modified  to  incorporate  label-­free  quantitation  
data.  
  
AE-­MS  analyses  identify  hundreds  of  new  mitochondrial  interactions  
To  assess  the  performance  of  our  approach  and  to  determine  an  appropriate  cutoff  score,  
we  focused  on  our  positive-­control  bait  proteins  that  have  known  binding  partners.  We  curated  a  
list   of   literature-­established   PPIs   involving   our   positive-­control   baits   and   compared   their  
CompPASS  scores  to  those  for  all  mitochondrial  preys  (Table  S2).  We  selected  a  stringent  cutoff  
score  that  achieved  93%  sensitivity  for  known  PPIs  while  simultaneously  eliminating  95%  of  all  
observed,  likely  background,  interactions  (Figure  2A).  
Applying  this  threshold  to  the  rest  of  our  data,  and  filtering  for  proteins  in  our  MitoCarta+  
list,  we  identified  1,829  interactions  from  a  total  observed  set  of  109,817  (Figure  2B,  Table  S3).  
Consistent  with  previous  efforts  (Jager  et  al.,  2012),  we  found  that  using  more  than  one  cell  type  
is  an  effective  means  for  identifying  and  prioritizing  interactions,  as  only  32%  of  interactions  are  
shared  between  the  cell  lines  when  limited  to  our  stringent  cutoff  score  (Figure  2C).  Changing  the  
carbon  source  (i.e.,  glucose  vs.  galactose)  had  a  more  modest  effect  with  61%  of   interactions  
shared  between  conditions  at  our  threshold  cutoff  (Figure  2D  and  S2);;  however,  the  abundances  
of  hundreds  of  these  shared  interactions  are  modulated  by  these  changing  conditions  (Figure  2E),  
suggesting   that   mitochondrial   metabolism   may   be   linked   to   the   regulation   of   protein-­protein  
interactions. Thus,   our   experimental   design   expanded   our   search   space,   enabled   the  
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identification   of   meaningful   interactions   by   excluding   nonspecific   background,   and   detected  
interactions  affected  by  nutrient  state. 
  
C17orf89  is  a  CI  assembly  factor  
We  designed  our  study  with  an  awareness  that  many  known  mitochondrial  pathways  and  
processes   are   “missing”   enzymes   or   functional   components   that   could   be   completed   by   our  
MXPs.  For  example,  45-­60%  of  biochemically-­validated  cases  of  CI  (Calvo  et  al.,  2010;;  Haack  et  
al.,  2011),  CII  (Jain-­Ghai  et  al.,  2013),  and  CIII  deficiency  (Fernandez-­Vizarra  and  Zeviani,  2015)  
lack  molecular  diagnoses.  As  such,  we  prioritized  MXPs   that   interacted  with   respiratory   chain  
components  for  functional  investigations.  
A   particularly   noteworthy   MXP   in   this   category   was   C17orf89,   a   7   kDa   protein   that  
interacted  with  the  known  CI  assembly  factor  (CIAF)  NDUFAF5  (Figure  3A).  Out  of  1415  observed  
preys   for   C17orf89,   31   mitochondrial   proteins   were   above   our   cutoff   score,   and   only   four  
interactions   were   observed   in   both   cell   lines.   Of   these,   the   highest-­scoring   interaction   was  
between  C17orf89  and  NDUFAF5.  Reciprocally,  only   three  mitochondrial  preys   interacted  with  
NDUFAF5  in  both  cell  lines,  one  of  which  was  C17orf89.  We  validated  this  C17orf89-­NDUFAF5  
interaction  by  showing  that   immunoprecipitation  of  FLAG-­tagged  C17orf89  from  HEK-­293  cells  
captured  endogenous  NDUFAF5  (Figure  3B).  
To  test  the  hypothesis  that  C17orf89  is  necessary  for  CI  activity,  we  used  RNAi  to  knock  
down   (KD)  C17orf89   expression   in  HEK-­293  cells  via   lentiviral   shRNA  constructs.   Indeed,  we  
found  that  silencing  of  C17orf89  had  a  dramatic  effect  on  CI  activity  (Figure  3C)  and  subunit  levels  
(Figure  S3A),  with  no  consistent  change  in  the  abundance  of  subunits  of  other  respiratory  chain  
complexes.  We  also  observed  a  slight  decrease   in   the  abundance  of  a  subunit  of  CIV  (Figure  
S3A)   and   of  CIV   activity   (Figure  S3B),   consistent  with   a   recent   study   suggesting   that   loss   of  
NDUFAF5  also  perturbs  CIV  (Saada  et  al.,  2012).  We  further  observed  a  dramatic  reduction  in  
the  oxygen  consumption  rates  of  live  C17orf89  KD  cells,  both  basally  and  upon  stimulation  with  
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the  uncoupler  FCCP  (Figure  3D),  without  change  to  the  extracellular  acidification  rate  (ECAR,  a  
measure   of   glycolytic   activity)   (Figure   S3C).   Notably,   transfection   of   C17orf89-­FLAG,   but   not  
GFP-­FLAG,  into  KD  cell  lines  was  able  to  rescue  much  of  the  lost  CI  activity  (Figure  3E).  
To   further   assess   the   functional   relationship   between   C17orf89   and   NDUFAF5,   we  
established  siRNA-­mediated  HEK-­293  KD  of  C17orf89,  NDUFAF4,  NDUFAF5,  NDUFAF6,  and  
the  CI  subunit  NDUFS3  (Figures  S4A-­E)  and  analyzed  each  using  mass  spectrometry.  Silencing  
of  the  target  genes  resulted  in  an  overall  decrease  in  CI  subunits;;  however,  the  pattern  of  subunit  
changes   for   the  C17orf89  kd  cells  was  most  similar   to   that  of  NDUFAF5   (Figure  S4F),   further  
strengthening  the  C17orf89–NDUFAF5  functional  relationship.  Strikingly,  silencing  of  C17orf89,  
but   not   other  CIAFs   or  NDUFS3,   resulted   in   a   drastic   loss   of   NDUFAF5   protein   (Figure   4A),  
suggesting   that   the   role   of   C17orf89   in   CI   assembly   likely   involves   the   direct   stabilization   of  
NDUFAF5.  
Our  implication  of  C17orf89  as  a  new  CI  assembly  factor  motivated  us  to  investigate  the  
possibility  that  its  disruption  might  contribute  to  unresolved  patient  cases  of  isolated  CI  deficiency.  
We   sequenced   C17orf89   in   125   such   cases   but   did   not   identify   likely   pathogenic   variants.  
However,   RNAseq   analysis   on   96   cell   lines   from   mitochondrial   disease   patients   that   had  
previously  been  analyzed  by  whole  exome  sequencing  revealed  one  case  that  exhibited  an  80%  
reduction  of  C17orf89  reads  (Figure  4B).  This  patient,  now  26  years  of  age,  was  born  to  unrelated  
parents   and   presented   in   childhood   with   acute   encephalopathy,   seizures,  mild   spasticity   and  
neuroradiological   features  consistent  with  a  diagnosis  of  Leigh  syndrome  (bilateral  high  signal  
intensities   in   the   basal   ganglia   and   brainstem);;   a   diagnostic   muscle   biopsy   at   the   age   of   14  
revealed  evidence  of  an  isolated  CI  defect  (<40%  control  activity;;  Figure  4C).  Respiratory  chain  
activities  were  normal  in  the  sequenced  cultured  skin  fibroblasts  (Figure  S4G),  as  is  the  case  for  
~50%  of  patients  exhibiting  a  respiratory  chain  defect  detected  in  skeletal  muscle,  liver,  or  heart  
(Kirby  et  al.,  2007),  thereby  precluding  our  ability  to  rescue  the  defect  by  reintroduction  of  wild  
type  C17orf89  cDNA.  Nonetheless,  based  on  its  key  role   in  CI  function  and  its   interaction  with  
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NDUFAF5   (Figure  4D),  we  propose   to   rename  C17orf89   as  NDUFAF8,   and  suggest   that   it   is  
candidate  gene  for  human  CI  deficiency.  
  
  LYRM5  binds  and  deflavinates  the  electron  transferring  flavoprotein    
A  second  MXP  that  our  AE-­MS  analyses  connected  to  the  respiratory  chain  is  LYRM5,  an  
11  kDa  member  of  the  mitochondrial  family  of  LYR  motif-­containing  (LYRM)  proteins,  which  also  
include   MXPs   LYRM1,   LYRM2,   and   LYRM9.   LYRM   proteins   were   first   identified   as  
supernumerary  subunits  of  CI  (NDUFA6  and  NDUFB9),  and  have  recently  been  found  to  act  as  
assembly  factors  for  CII  (SDHAF1/LYRM8,  SDHAF3/ACN9)  (Atkinson  et  al.,  2011;;  Ghezzi  et  al.,  
2009;;  Sánchez  et  al.,  2013),  CV  (FMC1)  (Lefebvre-­Legendre  et  al.,  2001),  and  iron-­sulfur  cluster  
biosynthetic  enzymes  (ISD11/LYRM4)  (Adam  et  al.,  2006;;  Shan  et  al.,  2007).  Our  data  captures  
many  of  these  expected  LYRM  interactions  (Figure  5A).  Interestingly,  all  seven  LYRM  proteins  in  
our  study  were  found  to  interact  with  NDUFAB1,  a  poorly  characterized  CI  subunit  that  also  serves  
as  an  acyl  carrier  protein  (Angerer  et  al.,  2014)  (Figure  5A).  
Unlike  the  other  LYRM  proteins,  LYRM5  interacted  robustly  with  ETFA  and  ETFB,  which  
comprise   the   electron   transfer   flavoprotein   (ETF)   (Figure   5A).   ETF   partners   with   ETF  
dehydrogenase  to  shuttle  electrons  to  CoQ.  Notably,  LYRM5-­FLAG  immunoprecipitation  enriched  
for   endogenous   ETFA   and   ETFB   to   a   much   greater   extend   than   does   IVD—a   known   ETF  
substrate  (Kim  and  Miura,  2004)  (Figure  5B,  S5).  Furthermore,  the  LYRM5  IP  elution  generated  
a  single  band  containing  LYRM5,  ETFA,  and  ETFB  on  a  BN-­PAGE  immunoblot  (Figure  5C).  To  
test  whether  the  LYRM5-­ETF  interaction  is  direct,  we  purified  recombinant  ETF  and  LYRM5  from  
E.   coli   (Figure   5D)   and   demonstrated   that   they   form   a   stable   complex   by   size-­exclusion  
chromatography  (Figure  5E).  LYRM5  alone  eluted  as  a  broad  peak  around  44kDa,  indicating  that  
it  may  exist  as  a  tetramer.  
Surprisingly,   the  purified  LYRM5-­ETF  complex   lacked   the  characteristic  yellow  color  of  
flavoproteins,   suggesting   that   LYRM5   either   prevents   the   incorporation   of   flavin   adenine  
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dinucleotide  (FAD)  into  ETF,  or  that  it  is  capable  of  removing  this  cofactor.  To  test  the  ability  of  
LYRM5  to  “deflavinate”   the  ETF  complex,  we  mixed  LYRM5  and  ETF  at   increasing  ratios  and  
measured  ETF  activity.  The  addition  of  LYRM5  led  to  a  linear  reduction  of  ETF  activity  up  to  a  
ratio   of   4:1,   at   which   point   ETF   lost   all   activity   (Figure   6A).   This   decrease   in   activity   was  
concomitant   with   a   proportional   release   of   FAD   from   the   ETF   complex,   as   observed   by  
fluorescence   emission   spectroscopy   (Figure   6B).   The   interaction   of   FAD   with   ETF   protein  
residues  can  be  seen  by   the  420  nm  and  460  nm  peaks  on  an  absorbance  spectrum.  These  
peaks   disappear   upon   addition   of   LYRM5   (Figure   6C),   lending   further   evidence   of   its   direct  
deflavination   activity.   Collectively,   these   experiments   support   a   direct,   specific   interaction  
between  LYRM5  and  ETF   that   results   in  deflavination   (Figure  6D)—a  unique  and  unexpected  
activity  that  perhaps  suggests  a  non-­electron  transferring  role  for  ETF  (see  discussion).  
  
CoQ  is  synthesized  by  a  dynamic  biosynthetic  complex  
Both  CI  and  ETF  operate  by  shuttling  electrons  to  CoQ—a  requisite  gateway  for  electron  transport  
along   the   mitochondrial   respiratory   chain.   CoQ   is   synthesized   within   the   mitochondrion   in   a  
process  that  involves  at  least  13  human  proteins,  six  of  which  we  consider  MXPs,  as  they  lack  
well   established   biochemical   roles   in   the   pathway   (Figure   S6A).   Across   a   series   of   isolated  
studies,  seven  S.  cerevisiae  CoQ  proteins,  Coq3p-­9p,  have  been  found  to  physically  interact  and  
to  potentially  form  a  biosynthetic  complex  (He  et  al.,  2014;;  Marbois  et  al.,  2005).  We  and  others  
have   speculated   that   a  CoQ   complex  might   exist   in   other   species;;   however,   species-­specific  
aspects  of  CoQ  biosynthesis  exist  and,  to  date,  there  are  only  four  known  human  CoQ-­related  
PPIs  (Ashraf  et  al.,  2013;;  Lohman  et  al.,  2014;;  Nguyen  et  al.,  2014).  
Our   AE-­MS   data   have   now   established   direct   evidence   of   a   highly   interconnected  
mammalian  CoQ  biosynthetic  complex,  which  we  call   complex  Q   (Figure  7A).   Intriguingly,   the  
abundances  of  CoQ  pathway  PPIs  involving  COQ8A/ADCK3  increased  in  galactose-­treated  cells,  
and   those   with   COQ8B/ADCK4   reciprocally   decreased   (Figure   7B)—a   phenomenon   that  
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accompanied  a  marked  elevation  of  CoQ  levels   in  HepG2  cells  (Figure  7C)  (Note  that  ADCK3  
and  ADCK4  are  now  referred  to  as  COQ8A  and  COQ8B,  respectively—see  Stefely,  et  al.  in  this  
issue).  We   consider   COQ8A   and  COQ8B   to   be  MXPs   due   to   their   lack   of   clear   biochemical  
function;;  however,  consistent  with  these  results,  we  recently  revealed  that  COQ8A  is  essential  for  
the  stability  of  CoQ  proteins  in  a  mouse  model  of  Coq8a  deficiency  (Stefely  et  al.,  this  issue  of  
Mol  Cell),  and  COQ8B  has  been  shown  to  interact  with  COQ6  (Ashraf  et  al.,  2013).  These  data  
suggest   an   important   connection   between   CoQ   production   and   interactions   among   CoQ  
biosynthetic   complex  members,   and  may   indicate   reciprocal   regulation   of   the   activities   of   the  
paralogous  COQ8A  and  COQ8B.  
We  next  aimed  to  reconstruct  the  CoQ  interactions  using  purified  recombinant  proteins.  
This   is   a   powerful   means   to   validate   our   observed   AE-­MS   interactions,   ascertain   the   direct  
interactions  between  the  CoQ  proteins,  and  begin  mapping  the  topology  of  complex  Q.  Our   in  
vitro  analyses   using   a   cell-­free   protein   translation   and   purification   system   revealed   that  while  
nearly  all  COQ  proteins  were  unstable  or   insoluble  when  produced  alone,  many  coexpression  
pairs   between   COQ3-­7   and   COQ9   were   stabilized   by   direct   interaction   (Figure   7D,E,   S6B).  
Strikingly,  using  this  same  method,  we  were  then  able  to  rebuild  a  CoQ  complex  containing  six  of  
the  core  members   in   vitro   (Figure  7G,H).  Combined  with   the  binary   interactions  noted  above,  
these  data  allow  us  to  propose  the  subunit  topology  of  the  complex  (Figure  7F,H).  While  it  is  likely  
that  other  CoQ-­related  proteins  interact  with  the  complex  directly  or  indirectly  and  are  important  
for  its  stability  in  vivo,  such  as  COQ8A  and  COQ8B,  this  work  suggests  that  these  six  core  CoQ-­
related   proteins   are   sufficient   to   form   a   complex.   These   data   lend   clarity   to   an   evolutionarily  
conserved   complex  Q  and   provide   a   platform   for   the   future   interrogation   of   the   roles   of   each  
complex  subunit,  including  the  MXPs  COQ4  and  COQ9.  
  
Associating  MXPs  with  other  established  pathways  
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Our  analyses  above  focused  on  MXPs  related  to  CI  and  CoQ  in  order  to  build  upon  our  recent  
work  in  these  areas  (Khadria  et  al.,  2014;;  Lohman  et  al.,  2014;;  Stefely  et  al.,  2015).  However,  our  
data  reveals  many  other  connections  between  MXPs  and  diverse  mitochondrial  processes.  For  
instance,  C15orf48  also   interacts  with  multiple  subunits  of  CI  and  CIV  (Figure  S7),  suggesting  
that   it   regulates   the   activity   of   one   or   both   of   these   complexes,   or   perhaps   supercomplex  
formation.  C2orf47   interacts  with  AFG3L2  and  SPG7,   the   two  members  of   the  human  m-­AAA  
protease  complex  that  is  responsible  for  the  maturation  of  several  membrane-­associated  proteins  
and   for   mitochondrial   protein   quality   processes   (Ehses   et   al.,   2009)   (Figure   S7).   As   a   final  
example,   we   observed   that   DHRS4—a   poorly   characterized   member   of   the   short-­chain  
dehydrogenases/reductases   (SDR)   family   (Persson   and   Kallberg,   2013)—interacts   with   other  
members  of  the  SDR  family,  including  DHRS4L2  and  CBR4,  as  well  as  with  SIRT3  and  EHHADH  
(Figure   S7).   DHRS4   is   reported   to   have   dual-­localization   to   peroxisomes   and   mitochondria  
(Matsunaga  et  al.,  2008;;  Pagliarini  et  al.,  2008),  and  is  dynamically  phosphorylated  and  acetylated  
(Grimsrud  et  al.,  2012;;  Still  et  al.,  2013);;  however,  no  direct  function  is  known.  These  interactions  
suggest  that  DHRS4  might  have  an  important  unappreciated  role  in  coordinating  lipid  metabolism  
between  these  organelles.  Our  other  top-­scoring  interactions,  and  many  others  that  fall  just  below  
our  stringent  cutoff,  can  likewise  enable  new  hypotheses  about  MXP  function  (Table  S2).  
  
DISCUSSION    
Insights  into  mitochondrial  respiratory  chain  function  
Our  identification  of  C17orf89/NDUFAF8  as  a  complex  I  assembly  factor  (CIAF)  pinpoints  
a  new  disease  gene  candidate  for  unresolved  cases  of  isolated  CI  deficiency.  Given  the  presence  
of   twin  CX9C   domains   in   its   primary   structure,   C17orf89/NDUFAF8   is   likely   a  member   of   the  
coiled-­coil-­helix-­coiled-­coil-­helix   (CHCH)   domain   family   of   proteins   (Modjtahedi   et   al.,   2016).  
Many  CHCH  proteins  are  mitochondrial,  and  several  are  involved  in  respiratory  chain  functions,  
including   four   CI   subunits   (Modjtahedi   et   al.,   2016).   Our   data   revealed   a   robust   interaction  
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between  C17orf89/NDUFAF8  and  NDUFAF5—a  putative  methyltransferase  that  is  essential  for  
early  stages  of  CI  assembly  (Pagliarini  et  al.,  2008;;  Sugiana  et  al.,  2008),  but  for  which  neither  a  
substrate  nor  a  direct  role   in  CI  maturation  have  been  elucidated.   Interestingly,  several  similar  
sub-­complexes  of  CIAFs  exist,  including  the  mitochondrial  CI  assembly  (MCIA)  complex  (Guarani  
et   al.,   2014),   and   the   NDUFAF3:NDUFAF4   complex   (Saada   et   al.,   2009).   Given   that  
C17orf89/NDUFAF8   interacts   with   and   stabilizes   NDUFAF5,   we   suggest   that   C17orf89   may  
facilitate  the  methyltransferase  activity  of  NDUFAF5,  or  even  be  its  substrate.  Furthermore,  as  we  
identified   a   patient   with   CI   deficiency   whose   molecular   diagnosis   eluded   whole   genome  
sequencing   but  who   is   deficient   in  C17orf89/NDUFAF8   transcript,  we   both   prioritize   this   as   a  
disease  gene  and  highlight  the  importance  of  complementary  methods  for  the  diagnosis  of  genetic  
diseases.  
CI   is  one  of  several  sources  of  electrons  entering  the  CoQ  pool   for   transport  along  the  
respiratory   chain.   A   second   source   is   ETF,   which   interacts   with   and   accepts   electrons   from  
various  mitochondrial  dehydrogenases  before  passing  them  to  ETFDH  (Roberts  et  al.,  1996).  ETF  
harbors  causal  mutations  in  glutaric  acidemia  type  2  (GA2)  (Vockley  and  Whiteman,  2002),  and  
other   cases   of   GA2   remain   unresolved   (Schiff   et   al.,   2006).   Given   this,   we   were   particularly  
interested  in  our  observed  interaction  of  ETF  with  LYRM5.  
We  discovered  that  the  interaction  between  LYRM5  and  ETF  results  in  an  efficient—and  
surprising—removal   of   FAD   from   the   ETF   holoenzyme.   Much   work   needs   to   be   done   to  
understand  the   in  vivo  utility  of  this  process,  but  a  few  possibilities  stand  out.  First,  the  FAD  of  
ETF  could  become  damaged  and  need  to  be  replaced.  Second,  removal  of  FAD  may  facilitate  
the  destabilization  of  ETF  and  allow  for  proteolysis  and  recycling  of  the  flavin  cofactor.  Third,  if  in  
a   given  metabolic   state  ETF   is   not   interacting  with   dehydrogenases   (i.e.,   its   electron   transfer  
partners),  its  FAD  would  be  free  to  interact  with  water  or  other  matrix  metabolites  and  generate  
reactive  oxygen  species  (Rodrigues  and  Gomes,  2012).  In  this  scenario,  LYRM5  could  act  to  shut  
down  ETF  activity  without  the  need  to  completely  turn  over  the  enzyme.  Finally,  it  is  possible  that  
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ETF   possesses   a   distinct,   non-­electron   transferring   function—a   possibility   we   most   favor.  
Consistent  with  this  hypothesis  is  our  observation  that  LYRM5,  like  other  LYRM  proteins  (Figure  
5A),   interacts   with   the   CI   subunit   NDUFAB1—the   mitochondrial   acyl   carrier   protein   (ACP)  
(Angerer,  2015;;  Angerer  et  al.,  2014).   It   is  possible  that  LYRM5  serves  as  an  adaptor  to  bring  
ETF  to  CI  via  NDUFAB1  to  perform  an  unidentified  function.  Given  our  functional  discoveries,  we  
propose   renaming  C17orf89   and   LYRM5   as   NDUF  Assembly   Factor   8   (NDUFAF8)   and   ETF  
Regulatory  Factor  1  (ETFRF1),  respectively.  
  
Insights  into  CoQ  biosynthesis  
CoQ  is  a  requisite  gateway  in  the  respiratory  chain  that  accepts  electrons  from  many  sources,  
including  CI  and  ETF  (via  ETFDH).  Although  it  was  discovered  60  years  ago,  multiple  aspects  of  
eukaryotic  CoQ  biosynthesis   remain   unexplained,   including   roles   for  MXPs  COQ8A,  COQ8B,  
COQ4,  and  COQ9  (Figure  S6A).  
Two   notable   features   emerged   from   our   work   with   the   CoQ   machinery.   First,   it   is  
abundantly  clear  that  the  mammalian  CoQ  proteins  physically  interact  to  form  what  appears  to  be  
a  biosynthetic  complex—complex  Q.  Saccharomyces  cerevisiae  is  also  known  to  have  a  partially-­
defined  complex,  but  it  is  not  known  how  this  complex  facilitates  CoQ  biosynthesis.  Our  work  here  
provides  new  insights  into  the  binary  interactions  that  likely  enable  the  formation  of  complex  Q  in  
both  species.  Second,  our  work  implicates  MXPs  ADCK3  and  ADCK4  (aka  COQ8A  and  COQ8B,  
respectively)  in  complex  Q,  and  show  that  their  interactions  with  the  complex  are  both  dynamic  
and  reciprocal.  COQ8A  and  COQ8B  are  paralogs  that  are  each  likely  orthologs  of  yeast  Coq8p,  
and  we  have  speculated  that  they  possess  redundant  functions  in  a  condition-­  or  tissue-­specific  
manner.  We  recently  have  shown  that  COQ8A  adopts  an  atypical  protein  kinase-­like  fold  (Stefely  
et  al.,  2015)  and,  building  off  of  the  work  here,  have  now  determined  that  its  function  is  essential  
for  maintaining  complex  Q  stability  (Stefely  et  al.,  this  issue  of  Mol  Cell).  
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Overall,  we  have  extended  the  annotation  of  the  mammalian  mitochondrial  proteome  by  
identifying   robust   PPIs   involving   MXPs   and   by   validating   roles   for   these   proteins   in   well-­
characterized  mitochondrial  pathways.  Other  prominent  PPIs   from  our  study  now  await   further  
biological  investigation,  and  many  more  that  fell  below  our  stringent  cutoff  score  will  nonetheless  
serve  as   important  clues  for   the  functional  annotation  of  MXPs  moving  forward  (Table  S3).  As  
such,  our  compendium  of  state-­specific  MXP  associations  will  continue  to  serve  as  a  powerful  
resource  for  the  characterization  of  mitochondrial  proteins,  thereby  advancing  our  understanding  
of  basic  mitochondrial  biology  and  its  associated  pathophysiology.  
  
EXPERIMENTAL  PROCEDURES  
Mitochondrial  proteome  compilation  
Entrez  GeneIDs  of  the  mouse  MitoCarta  (Pagliarini  et  al.,  2008)  were  converted  from  mouse  to  
human  using  HomoloGene  and  reciprocal  BLASTP  searches.  Data  from  the  mitochondrial  matrix  
(Rhee  et  al.,  2013),  and  inter-­membrane  space  (Hung  et  al.,  2014)  proteomic  studies,  and  other  
high-­quality  studies,  were  then  integrated  with  the  human  MitoCarta  2.0  (Calvo  et  al.,  2016)  to  
generate  our  MitoCarta+  list  of  mitochondrial  proteins.  
  
Generation  of  tagged  constructs  
Mitochondrial  open  reading  frames  were  obtained  from  The  Broad  Institute  and  DNASU  (Seiler  
et  al.,  2014)  and  cloned  into  a  pcDNA3.1  mammalian  expression  vector  with  a  C-­terminal  FLAG  
tag.  
  
Mammalian  cell  culture  
HEK293  or  HepG2  cells  were  transiently  transfected  with  pcDNA3.1  gene-­FLAG  plasmids  using  
linear  polyethylenimine  (PEI,  PolySciences)  and  Opti-­MEM  (LifeTechnologies).  After  48  hours,  
cells   were   washed   with   PBS   and   media   was   replaced   with   DMEM   containing   either   10   mM  
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glucose   or   10   mM   galactose.   After   24   hours,   cells   were   washed   with   and   harvested   into  




Cell   pellets   were   lysed   in   200   μL   buffer   (see   supplemental   experimental   procedures).   After  
vortexing  on  ice,  insoluble  materials  were  pelleted  (16,000  g,  10  min,  4°C).  Equal  masses  of  cell  
supernatant  were  mixed  with  30  μL  pre-­washed  anti-­FLAG  magnetic  beads  (Sigma  M8823)  for  2-­
3  h  at  4°C  with  end-­over-­end  agitation.  Following  incubation,  beads  were  washed  four  times  and  
proteins  were  eluted   in  70  μL  elution  buffer  containing  0.2  mg/mL  FLAG-­peptide   for  30  min  at  
room  temperature  with  constant  agitation.  
  
LC-­MS/MS  analysis  
All   experiments   were   performed   using   a   NanoAcquity   UPLC   system   (Waters,   Milford,   MA)  
coupled   to   an   Orbitrap   Elite   mass   spectrometer   (Thermo   Fisher   Scientific,   San   Jose,   CA).  
Reverse-­phase   columns  were  made   in-­house   by   packing   a   fused   silica   capillary  with   3.5   μm  
diameter,  130  Å  pore  size  Bridged  Ethylene  Hybrid  C18  particles  (Waters)  to  a  final  length  of  30  
cm.   The   column   was   heated   to   55°C   for   all   experiments.   Precursor   trypsin   digested   peptide  
cations   were   generated   from   the   eluent   through   the   utilization   of   a   nanoESI   source.   Mass  
spectrometry  instrument  methods  consisted  of  MS1  survey  scans  that  were  used  to  guide  fifteen  
subsequent   data-­dependent   MS/MS   scans.   Raw   data   can   be   found   on   Chorus  
(https://chorusproject.org)  under  project  ID  1043.  
  
Data  Analysis  
Data  was  processed  using  the  MaxQuant  software  suite  (Cox  and  Mann,  2008;;  Cox  et  al.,  2011).  
Searches  were  performed  against  a   target-­decoy  database  using   the  default  settings   for  high-­
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resolution  mass  spectra.  Results  were  filtered  to  1%  FDR  at  the  unique  peptide  level  and  grouped  
into  proteins  within  MaxQuant.  Proteins  were  quantified  across  all  replicates  within  each  bait  set  
using  MaxLFQ  (Cox  et  al.,  2014).  
  
Generation  of  C17orf89  knockdown  cells  
Viral   particles   were   produced   in   HEK293   cells   by   transient   transfection   with   PEI   of   lentiviral  
shRNA  construct,  psPAX2,  and  pMD2.G  packaging  plasmids.  HEK293  cells  were  transduced  in  
6-­well  plates  and  were  selected  in  culture  medium  supplemented  with  2  μg/ml  puromycin  for  at  
least   two  weeks.  For  siRNA  knockdowns,  HEK293  cells  were   transfected  with  10  nM  RNA  for  
each  target  or  the  Non-­Targeting  siRNA  based  on  the  manufacturer’s  protocol.  After  2  days,  the  
cells   were   passaged,   and   the   next   day   were   transfected   again   with   10   nM   siRNA,   and   after  
another  2  days  were  collected  for  real-­time  qPCR,   immunoblot,  and  mass  spectrometry-­based  
proteomic  analyses.  
  
CI  activity  and  C17orf89  sequencing  and  expression  analysis  
Patients  with  biochemical  evidence  of  isolated  complex  I  deficiency  identified  via  diagnostic  work-­
up   for   suspected  mitochondrial   disease  were   screened   for   disruptive   variants   in  C17orf89   by  
Sanger  sequencing  (primers  available  on  request).  C17orf89  transcript  abundance  in  control  and  
patient  lines  was  measured  as  described  previously  (Haack  et  al.,  2015).  
  
Purification  and  functional  analyses  of  LYRM5  and  ETF  
LYRM5  was  cloned  into  a  pET28a  vector  and  purified  as  an  N-­terminally  His-­tagged  protein  by  
immobilized  metal  affinity  chromatography.  Size  exclusion  chromatography  was  performed  using  
a   Pharmacia   300X10mm   Superdex   200   column.   ETF   activity   +/-­   LYRM5   was   measured   by  
monitoring  DCPIP  reduction  at  600  nm.  For  assay  conditions,  40μM  DCPIP,  20uM  C8-­CoA,  and  
0.1~0.2μM  ETF  were  mixed  in  20mM  Tris-­HCl  buffer,  pH  8.0.  The  assay  reactions  were  initiated  
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by  adding  0.2μM  MCAD  and  the  UV  absorbance  decrease  at  600nm  was  followed  for  3  minutes.  
FAD   release  was  measured   by   first  mixing   10   μM  ETF  with   varying   amounts   of   LYRM5   and  
incubated  on  ice  for  2  hours.  The  samples  were  then  diluted  5  times  in  20  mM  Tris-­HCl  buffer  (pH  
8.0)  and  the  fluorescence  emission  spectra  were  taken  at  room  temperature  (λex  =  436nm).  Visible  
spectra  measurements   of   10   μM  ETF  was  measured   in   the   presence   of   0,   20μM   and   40μM  
LYRM5  in  20mM  Tris-­HCl  buffer,  pH  8.0.  
  
Blue  Native-­PAGE  
Samples  were  mixed  with  NativePAGE  sample  buffer  to  1x  final  concentration,  and  were  loaded  
onto  NativePAGE  gels  alongside  NativeMARK  standard.  Gels  were  run  for  a  total  of  two  hours  
and  subsequently  subjected  to  western  analysis.  
  
Coenzyme  Q  Quantification  
Tissue  culture  cells  were  lysed  by  vortexing  with  glass  beads  and  spiked  with  an  internal  standard  
(CoQ6).  Lipids  were  extracted  with  CHCl3/MeOH  (1:1,  v/v)  and  analyzed  by  LC-­MS/MS.  
  
Cell-­free  expression  and  purification  
Purified   plasmid   DNA   was   used   as   individual   transcription   templates   with   SP6   RNase  
polymerase.  Transcription  and   translation  methods  are  as  previously  described  (Makino  et  al.,  
2013).  
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Figure  1.  AE-­MS  methodology  
(A)  Schematic  workflow  of  the  AE-­MS  method.  
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(B)  Localization  of  all  FLAG-­tagged  constructs  was  established  based  on  MLS-­GFP  and  anti-­
FLAG   fluorescence  microscopy   (see  Figure  S1).  Venn  diagrams   report   the  percentage  of   the  
MitoCarta+  list  (Table  S1)  associated  with  each  category.  
(C)  Galactose   induces  mitochondrial   respiration.  Ratio  of   rates  of  oxygen  consumption   (OCR)  
and  extracellular  acidification  (ECAR)  in  HEK293  (left)  and  HepG2  (right)  cells  grown  in  10  mM  
glucose   (Glu)   or   galactose   (Gal)   for   24   hours   prior   to   assay.   OCR/ECAR   is   proportional   to  
mitochondrial  vs.  glycolytic  flux  (*  indicates  t-­test  p-­value  <  0.05). Error  bars  indicate  ±  SEM.  
  
Figure  2.  Overall  analyses  of  our  AE-­MS  approach    
(A)   CompPASS   scoring   accuracy.   CompPASS   scores   were   calculated   for   all   bait-­prey  
interactions,   including   those   involving   only  mitochondrial   prey   (gray),   and   those   determined  a  
priori   to  be  high-­confidence  PPIs  based  on   the   literature   (black).  At  each  score   threshold,   the  
percent   of   remaining   PPI   per   bin   was   calculated.   Scores   to   the   right   of   the   vertical   gray   bar  
exceeded  the  threshold  set  for  this  study  and  are  counted  as  high-­confidence  interactions.  
(B)  Quantitative  scoring  enriches  for  high-­confidence  interactors.  Top:  Schematic  of  the  results  of  
CompPASS  score  filtering.  Bottom  left:  Heat  map  where  white  indicates  a  prey  was  not  observed,  
and  shades  of  gray  indicate  quantified  abundance.  Prey  proteins  are  in  rows,  and  FLAG-­tagged  
baits  are  in  columns.  Data  are  averages  from  6  replicates  per  cell  line  (3  glucose,  3  galactose).  
Bottom   right:   Heat   map   showing   scores   above   CompPASS   threshold.   Preys   and   baits   are  
organized  in  the  same  order  as  in  left  heat  map.  Black  indicates  a  score  above  the  threshold.  
(C)  Venn  diagram  of  high-­confidence  PPIs  from  each  cell  line.  Mitochondrial  interactions  above  
threshold  in  HEK293  (blue)  and  HepG2  (green)  cells  are  indicated  (see  Figure  S2).  
(D)  Venn  diagram  of  high-­confidence  PPIs  from  each  carbon  source.  Mitochondrial  interactions  
above  threshold  in  glucose  (orange)  and  galactose  (purple)  cells  are  indicated.  
(E)  Histogram  of  the  fold  change  abundances  of  PPIs  between  carbon  sources.  Select  dynamic  
PPIs  involving  proteins  from  the  coenzyme  Q  biosynthetic  pathway  (see  Figure  S7)  are  indicated.  
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Figure  3.  C17orf89  is  required  for  complex  I  assembly.  
(A)  Schematic  of  top-­scoring  C17orf89  interactions.  Arrows  originate  from  bait  proteins  and  point  
to  high-­confidence  interactors.  
(B)  Immunoblot  of  immunoprecipitated  FLAG-­tagged  C17orf89,  LYRM5,  and  MLS-­GFP  with  anti-­
FLAG  (red)  or  anti-­NDUFAF5  (green).  
(C)  Activity  of  complex  I  in  C17orf89  knock  down  (kd)  and  control  (c)  HEK293  cell  lines  and  control  
lines.  Error  bars  indicate  ±  SD  (see  also  Figure  S3).  
(D)  Measurement  of  oxygen  consumption  rate  (OCR)  for  the  same  kd  or  c  lines  as  in  (C)  using  a  
Seahorse   Extracellular   Flux   Analyzer   (FCCP,   carbonyl   cyanide   p-­
trifluoromethoxyphenylhydrazone).  Error  bars  indicate  ±  SEM.  
(E)  Complex  I  activity  in  kd  and  c  cell  lines  after  transfection  with  GFP-­FLAG  (negative  control)  or  
C17orf89-­FLAG  (rescue).  Error  bars  indicate  ±  SD.  
  
Figure  4.  C17orf89  stabilizes  NDUFAF5  and  is  depleted  in  a  case  of  CI  deficiency  
(A)   Immunoblots  of  mitochondrial  proteins   in  cells   treated  with  siRNA   for  CI  and  CIAF  genes.  
C17orf89  knockdown  results  in  loss  of  CI  subunits  and  a  marked  depletion  of  NDUFAF5  (red  box).  
See  also  Figure  S4.  
(B)  RNAseq  analysis  of  C17orf89  expression  in  96  cell  lines  from  patients  with  respiratory  chain  
dysfunction  (RPKM,  Reads  Per  Kilobase  of  transcript  per  Million  mapped  reads).  Arrow  indicates  
a  line  with  severe  loss  of  C17orf89  expression.  
(C)  Respiratory  chain  complex  analyses  of  the  patient  line  indicated  in  (B),  revealing  an  isolated  
CI  deficiency  (P,  patient;;  C,  control).  Error  bars  represent  mean  +/-­  SD,  n=25.  
(D)  Proposed  model  of  C17orf89–NDUFAF5  complex  function  in  CI  assembly.  
  
Figure  5.  LYRM5  forms  a  complex  with  ETF  
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(A)  Schematic  of  top-­scoring  LYRM  PPIs.  LYRM5-­ETF  interactions  are  shaded.  
(B)  Validation  of  the  interaction  between  LYRM5  and  both  ETFA  and  ETFB.  C-­terminally  FLAG-­
tagged   GFP,   IVD,   NDUFA4,   and   LYRM5   were   immunoprecipitated   (IP)   from   HEK   cells   and  
immunoblotted  (IB)  with  anti-­ETFA  and  anti-­ETFB  (upper)  or  anti-­FLAG  (lower).  LYRM5  enriched  
for  both  ETF  proteins  more  efficiently  than  IVD,  a  known  ETF  interactor.  
(C)  IP  of  LYRM5-­FLAG  or  MLS-­GFP-­FLAG  from  HEK293  cells  analyzed  by  Blue  Native-­PAGE  
analysis  and  IB.  The  same  membrane  was  blotted  for  ETFB  (left)  and  then  FLAG  (right)  (see  also  
Figure  S5).  
(D)  Recombinant  N-­terminally  His-­tagged  LYRM5  and  untagged  ETFA/B  were  co-­expressed  in  
E.   coli.   Purification   of   LYRM5   by   metal   affinity   chromatography   led   to   the   co-­purification   of  
ETFA/B.  
(E)  LYRM5  and  ETF   form  a  stable  complex.  Size  exclusion  chromatography  of  LYRM5  alone  
(red),  ETF  alone  (green),  or  the  co-­purified  LYRM5-­ETF  complex  (blue)  noted  in  (D).  
  
Figure  6.  LYRM5  deflavinates  ETF.  
(A)   ETF   activity   in   the   presence   of   increasing   amounts   of   LYRM5   (±   SD   from   triplicate  
measurements).  
(B)   FAD   release   from   ETF   upon   incubation   with   varying   amounts   of   LYRM5,   measured   by  
fluorescence  emission  spectroscopy.  
(C)  Visible   spectra   of  ETF   in   the  presence  of   LYRM5.  The   flavin   visible   spectrum  shows   two  
shoulder   peaks   at   420nm   and   460nm   due   to   the   interaction   between   FAD   and   ETF   protein  
residues  that  are  lost  upon  addition  of  LYRM5.  Spectrum  a,  b,  and  c  are  for  LYRM5:ETF  ratios  of  
0,  2,  and  4,  respectively.  For  clarity,  spectra  a  and  b  have  been  shifted  by  +0.04  and  0.02  OD  
units,  respectively.  
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(D)  Proposed  model  of  the  functional  interaction  between  LYRM5  and  ETF.  Binding  of  four  molar  
equivalents  of  LYRM5  (red  dot)  to  ETF  (green  trace  of  PDB  ID  1EFV)  leads  to  the  loss  of  FAD  
from  ETF  (F).  
  
Figure  7.  Interaction  analysis  reveals  the  dynamic  human  CoQ-­related  complex  
(A)  All  CoQ-­related  proteins  used  as  baits  and/or  observed  as  preys  in  this  study  are  shown  as  
white  nodes.   Interactions  above  our  score   threshold  are  shown  for  HEK  cells   (gray  arrows)  or  
HepG2  cells  (green  arrows).  
(B)  CoQ-­related  interactions  involving  COQ8A  or  COQ8B  as  bait  were  assessed  for  the  effect  of  
cellular  metabolic  status.  Interactions  more  abundant  in  galactose  or  glucose  media  are  shown  in  
red  or  blue,  respectively,  while  those  with  no  clear  media  effect  are  in  white.  
(C)  Relative  abundance  of  CoQ10  in  HEK293  and  HepG2  cells  after  treatment  with  10  mM  glucose  
or   galactose   for   24   hours   (***   indicates   t-­test   p-­value   <   0.001,   error   bars   indicate   the   95%  
confidence  interval).  
(D-­E)   Representative   results   of   in   vitro   protein   translation   and   purification   of   each   core   CoQ  
complex  protein  individually  (D)  or  in  pairs  (E).  Proteins  were  run  on  SDS-­PAGE  and  detected  by  
Coomassie  stain.  See  Figure  S6  for  all  interactions  observed.  
(F)   Schematic   of   COQ   protein   network   direct   interactions   established   in   vitro.   All   robust  
interactions  are  represented  as  edges  between  the  COQ  protein  nodes.  
(G)  In  vitro  co-­purification  of  all  six  core  COQ  complex  proteins.  
(H)  Three-­dimensional  model  of  predicted  COQ  complex  structure  based  on   in  vitro   interaction  










 Figure  S1,  related  to  Figure  1
     
 Figure  S1,  related  to  Figure  1.  Mitochondrial  localization  of  baits  used  in  this  study.  
Epifluorescence  microscopy   images  showing   the  mitochondrial   localization  of  all  FLAG-­tagged  
baits  used   in   this  study.  Merged   images  show   the  mitochondria-­localized  GFP  signal   in  green  
(Mito),   the  FLAG-­tagged  protein   in   red  (FLAG)  and   the  nucleus   in  blue  (DNA).  Regions  of  co-­
localization  appear  yellow.  
     
 Figure  S2,  related  to  Figure  2  
  
Figure  S2,  related  to  Figure  2.  Effects  of  conditions  and  replicates  on  AE-­MS  analyses.  
Venn  diagrams  showing  the  interactions  identified  when  only  subsets  of  our  data  are  used.  Dark  
blue  represents  interactions  identified  in  HEK293  cells  grown  in  glucose,  light  blue  is  HEK293  in  
galactose,   dark   green   is   HepG2   in   glucose,   and   light   green   is   HepG2   in   galactose.   Grey  
represents  the  overlap  in  interactions  between  two  groups.  
 Figure  S3,  related  to  Figure  3  
  
  
Figure  S3,  related  to  Figure  3.  Functional  assays  implicating  C17orf89  in  CI  assembly.  
(A)  Abundance  of  core  OxPhos  complex  subunits  in  C17orf89  knock  down  (kd)  and  control  (c)  
HEK293  cell  lines  (ns,  non-­specific  band).  Each  gel  lane  is  aligned  to  the  activity  data  in  (B).    
(B)  Complex   I   (CI)  and  complex   IV   (CIV)  assays   for  C17orf89  knockdown  (kd)  and  control   (c)  
cells  as  described  in  Figure  6A  of  the  main  text.  Error  bars  indicate  ±  standard  deviation.  
(C)   Extracellular   acidification   rate   (ECAR)   measurements   of   C17orf89   knockdown   (kd)   and  
control  (c)  cells  as  described  in  Figure  3D  of  the  main  text.  Error  bars  indicate  ±  standard  error  
of  the  mean.  
     
   
Figure  S4,  related  to  Figure  4  
  
Figure  S4,  related  to  Figure  4.  Knockdown  of  C17orf89  causes  a  tissue-­specific  CI  defect  
that  is  similar  to  the  loss  of  NDUFAF5.  
(A-­E)  Relative  mRNA  abundance  of  the  indicated  siRNA  targets  across  siRNA  transfections  as  
assessed  by  real-­time  qPCR.  (F)  Clustered  heat  map  of  CI  protein  subunit  levels  in  CI  or  CIAF  
KD   cells   detected   via  MS.   (G)   Respiratory   chain   complex   activity   for   fibroblasts   from   patient  
described  in  Figure  4.  
     




Figure  S5,  related  to  Figure  5.  ETFB  is  also  present  in  a  complex  immunoprecipitated  by  
LYRM5/ETFBP.  
The  same  sample  IP  eluate  shown  in  Figure  5C  was  loaded  onto  a  separate  native  gel  and  
immunoblotted  for  ETFB.  
     





     
Figure   S6,   related   to   Figure   7.   Analysis   of  
binary   interactions   between   CoQ-­related  
proteins.  
(A)  Overview  of   the  coenzyme  Q  biosynthesis  
pathway.  Steps  of  the  pathway  that  are  not  yet  
associated   with   a   mitochondrial   protein   are  
indicated   by   a   question   mark   (?).   MXPs  
related  to  the  CoQ  pathway  are  boxed  in  red.    
(B)   Analyses   of   COQ   protein   pairwise  
interactions  using  wheat  germ  cell-­free  protein  
translation   and   purification.   The   protein   listed  
above   each   gel   was   included   in   each   lane.  
Numbers   above   each   lane   correspond   to  
another   COQ   protein   that   was   co-­translated  
and   co-­purified   with   the   protein   listed   above  
each   gel   (e.g.,   “4”   indicates   “COQ4”;;   “-­“  
indicates   that   no   other   protein   was   included).  
Numbers   to   the   sides   of   gels   are   molecular  
weights  in  kilodaltons.  
 




Figure  S7,  related  to  figures  3,  5,  and  7.  Overview  of  select  interactions  identified  within  
our   data.   Red   circles   indicate   MXPs   used   as   bait   proteins   in   this   study.   Arrows   indicate  
interactions  of  MXPs  with   the  corresponding  mitochondrial  proteins  or  complexes.  Complex  Q  
(Q),  which  involves  many  interactions  identified  in  this  study,  is  depicted  in  a  simplified  form.  
     
 SUPPLEMENTAL  TABLE  LEGENDS  
 
Table S1. MitoCarta+ list, related to Figure 1A and 1B. 
Table of our MitoCarta+ list of 1,166 human proteins with validated mitochondrial localization including the 50 
MXPs and 27 mitochondrial proteins of known function used as baits in this study. 
 
Table S2. Control PPI list, related to Figure 2A. 
Table of literature-established protein-protein interactions (PPIs) involving our positive-control baits. 
 
Table S3. PPIs established in this study, related to Figure 2. 
Table of 109,817 PPIs identified in this study, including 1,829 above our CompPASS threshold score. 
 SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Mitochondrial proteome compilation and disease association 
The mouse MitoCarta 2.0 (Mouse.MitoCarta2.0.xls) was downloaded from The Broad Institute 
(http://www.broadinstitute.org/pubs/MitoCarta/) and Entrez GeneIDs were converted from mouse to human using 
HomoloGene (build 68) and reciprocal BLASTp searches. Data from the mitochondrial matrix (Rhee et al., 2013) 
and inter-membrane space (Hung et al., 2014) proteomic studies were then integrated with the human MitoCarta. 
This list of 1,167 human mitochondrial proteins was used as the basis for subsequent determination of subcellular 
localization. We further annotated these MXPs by assessing their prior association with disease. Many 
mitochondrial proteins are associated with disease, often with no clear pathological mechanism (Koopman et al., 
2012). To connect mitochondrial proteins with their associated pathology, we mapped large-scale disease lists onto 
our list of mitochondrial proteins (Amberger et al., 2015; Rath et al., 2012; Safran et al., 2010). We found that 368 
mitochondrial proteins are associated with more than 300 human disease states. Notably, despite little to no 
mechanistic knowledge of their function, we observe that mutations in 29 of our MXPs are causal for disease 
phenotypes as listed in OMIM and many more have been associated with diseases.  
 
 
Identification of mitochondrial disease-related genes 
Disease-gene annotations were downloaded from OMIM (Amberger et al., 2015), Orphanet (Rath et al., 2012) 
(downloaded March 2015) and GeneCards/MalaCards (Rappaport et al., 2014; Safran et al., 2010) (Koopman et al., 
2012). 
 
Generation of tagged constructs 
Mitochondrial open reading frames were obtained from The Broad Institute and DNASU (Seiler et al., 2014). 
Sequences were compared against UniProt (UniProt, 2015) and dbSNP (Sherry et al., 2001). Any remaining 
mutations of question were assessed for evolutionary conservation using Homologene. Site-directed mutagenesis 
was performed by QuikChange PCR and primers were designed by PrimerX software: 
http://www.bioinformatics.org/primerx/. 
 
Mammalian cell culture 
HEK293 and HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM, LifeTechnologies) 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (LifeTechnologies). Cells were 
subcultured by trypsinization. On day one, 7 million HEK HepG2 cells were plated in a 15 cm dish and allowed to 
grow overnight. On day two, cells were transiently transfected with a mix of 20 µg pcDNA3.1 gene-FLAG plasmid, 
72 µg linear polyethylenimine (PEI, PolySciences), and 900 µL Opti-MEM (LifeTechnologies). On day four, cells 
were washed with PBS and media was replaced with DMEM containing 10% FBS, 1% penicillin-streptomycin, and 
either 10 mM glucose or 10 mM galactose. After 24 hours (Day 5), cells were washed with and harvested into 
phosphate-buffered saline (PBS), were collected at 2,000 rcf, were snap frozen in liquid nitrogen, and were stored at 
-80°C. 
 
Subcellular localization analysis 
On the day prior to transfection, HEK293 cells were plated at a density of 75,000 cells/well onto poly-D-lysine-
coated coverslips in 6-well dishes. Cells were transiently transfected with a mix of 1 µg pcDNA3.1 gene-FLAG, 0.5 
µg plasmid encoding green fluorescent protein with an N-terminal mitochondrial localization sequence (MLS-GFP) 
(Hanson et al., 2004), 7.5 µg PEI, or Lipofectamine LTX Plus (Life Technologies), and 200 µL Opti-MEM. After 24 
hours, the cells were fixed (4% paraformaldehyde in PBS), permeabilized (0.2% Triton X-100 in PBS), blocked (1% 
BSA in PBS), and probed with mouse anti-FLAG M2 1° antibody (F1804, Sigma, 1:2000 (v/v) in 1% BSA in PBS) 
and either Alexa Fluor 594 or 564-conjugated goat anti-mouse 2° antibody (LifeTechnologies, 1:2000 (v/v) in 1% 
BSA in PBS) in 1% BSA in PBS. Cells were either counter stained with Hoechst dye (1 µg/mL) to label nuclear 
 DNA and placed in mounting medium (1:1, v/v, glycerol/PBS), or mounted in ProLong Diamond Antifade 
Mountant with DAPI (Life Technologies). Epifluorescent microscopy was performed on an Olympus IX81 




Cell pellets were lysed in 200 µL cold lysis buffer (20 mM HEPES, pH 7.40, 100 mM NaCl, 10% glycerol, 3% 
digitonin (Sigma), 1 mM DTT, protease inhibitors (10 µM benzamide HCl, 1 µg/mL 1,10-phenanthroline and 0.5 
µg/mL each of pepstatin A, chymostatin, antipain, leupeptin, aprotinin; Sigma), phosphatase inhibitors (500 µM 
imidazole, 250 µM NaF, 300 µM sodium molybdate, 250 µM sodium orthovanadate, 1 mM sodium tartrate; Sigma), 
and deacetylase inhibitors (10 mM each sodium butyrate and nicotinamide; Sigma)), modified from Marbois et al 
(Marbois et al., 2005). After periodic vortexing on ice, insoluble materials were pelleted (16,000 g, 10 min, 4°C) and 
the supernatant was retained. The protein concentration was quantified by Bradford assay, and equal masses of cell 
supernatant were mixed with 30 µL pre-washed anti-FLAG magnetic beads (Sigma M8823) for 2-3 h at 4°C with 
end-over-end agitation. Following incubation, beads were washed four times in wash buffer (20 mM HEPES, pH 
7.40, 100 mM NaCl, 0.05% digitonin, 10% glycerol) and once in final wash buffer (20 mM HEPES, pH 7.40, 100 
mM NaCl). Proteins were eluted in 70 µL elution buffer (final wash plus 0.2 mg/mL FLAG-peptide) for 30 min at 
room temperature with constant agitation. 
 
Quantitative mass spectrometry 
Protein digestion 
Protein pull-downs (40 µL volume) were transferred from 96-well plates to separate 1.5 mL tubes (Eppendorf) 
containing 40 µL of 3 M Urea, 100 mM Tris (pH 8). Protein was reduced with 5 mM dithiothreitol (incubation at 
37°C for 45 minutes) and alkylated with 15 mM iodoacetamide (incubation in the dark, at ambient temperature, for 
45 minutes). Alkylation was quenched by adding an additional 5 mM dithiothreitol (incubation at ambient 
temperature for 15 minutes). Protein was enzymatically digested with 0.8 µg of sequencing-grade trypsin (Promega, 
Madison, WI) and incubated at ambient temperature overnight. An additional 0.4 µg of trypsin was added to each 
sample the next morning and the resulting mixtures were incubated at room temperature for an hour. Digests were 
quenched by bringing the pH 2 with trifluoroacetic acid and immediately desalted using C18 solid-phase extraction 
columns (SepPak, Waters, Milford, MA). Prior to washing peptides with 3 mL of 0.1% TFA on the C18 columns, 
peptides were washed with 1 mL of 5% acetonitrile/0.1% TFA solution to reduce the abundance of the 1x FLAG 
peptide from each mixture. 
 
CIAF KD cell pellets prepared by pellets were resuspended in 1 mL of 8 M Urea, 40 mM Tris, pH 8, 30 mM sodium 
chloride, 1 mM calcium chloride and 1 tab protease inhibitor (Roche, Indianapolis, IN). Protein was extracted with 9 
mL of methanol (1:10 ratio) and pelleted at 3,500 RPM for 40 minutes. Pellets were air dried for 40 minutes then 
resuspended in 8 M Urea, 100 mM Tris. Protein concentration was determined through a BCA assay (Thermo Fisher 
Scientific). Protein (0.5 mg) was reduced with 10 mM TCEP and alkylated with 40 mM chloroacetamide at room 
temperature. Samples were diluted to 1.5 M Urea with 100 mM Tris, pH 8, and then protein was enzymatically 
digested with sequencing-grade trypsin in a 1:50 enzyme to protein ratio (Promega, Madison, WI). An additional 
1:100 enzyme to protein ratio of sequencing-grade trypsin was added in the morning. Digests were quenched by 
bringing the pH to 2 with trifluoroacetic acid and immediately desalted using polymeric reversed phase solid-phase 
extraction columns (StrataX, Phenomenex, Torrance, CA). Peptides were washing with 3 mL of 0.1% TFA and 
eluted from the columns. Prior to LC-MS/MS analysis, peptide concentration was determined using a quantitative 
colorimetric peptide assay (Thermo Fisher Scientific).  
 
LC-MS/MS analysis of Protein-Protein interactions 
All AE-MS/MS experiments were performed using a NanoAcquity UPLC system (Waters, Milford, MA) coupled to 
an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Reverse-phase columns were made 
 in-house by packing a fused silica capillary (75 µm i.d., 360 µm o.d., with a laser-pulled electrospray tip) with 3.5 
µm diameter, 130 Å pore size Bridged Ethylene Hybrid C18 particles (Waters) to a final length of 30 cm. The 
column was heated to 55°C for all experiments. Samples were loaded onto the column for 12 minutes in 95:5 buffer 
A [water, 0.2% formic acid, and 5% DMSO] : buffer B [acetonitrile, 0.2% formic acid, and 5% DMSO] at a flow-
rate of 0.40 µL/min. Peptides were eluted using the following gradient: an increase to 22% B over 32 min, followed 
by a 5 min linear gradient from 22% to 28% B, followed by a 3 min linear gradient from 28% to 70% B which was 
held for 3 minutes. The column was equilibrated with 5% buffer B for an additional 15 min. Precursor peptide 
cations were generated from the eluent through the utilization of a nanoESI source. Between each set of baits a 3 run 
wash sequence was utilized to minimize carryover. The first wash consisted of trapping acetonitrile for 25 minutes 
and the second was cycle consisted of a 45 min high organic gradient. A pre-blank wash was run by injecting 4.5 uL 
0.2% formic acid using the 60 minute gradient described above to allow the identification of carryover proteins.   
Mass spectrometry instrument methods consisted of MS1 survey scans (1x106 target value; 60,000 
resolution; 300 Th – 1500 Th) that were used to guide fifteen subsequent data-dependent MS/MS scans (2 Th 
isolation window, HCD fragmentation, normalized collision energy of 30; 5x104 target value, 15,000 resolution). 
Dynamic exclusion duration was set to 45 s, with a maximum exclusion list of 500 and an exclusion width of ±10 
ppm around the selected average mass. Maximum injection times were set to 50 ms for all MS1 scans and 200 ms 
for MS/MS scans. 
All CIAF KD experiments were performed on a Dionex UPLC system (Thermo Scientific, San Jose, CA) 
coupled to an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Reverse-phase columns 
were made in-house by packing a fused silica capillary (75 µm i.d., 360 µm o.d., with a laser-pulled electrospray tip) 
with 1.7 µm diameter, 130 Å pore size Bridged Ethylene Hybrid C18 particles (Waters) to a final length of 30 cm. 
The column was heated to 65°C.  
Samples were loaded onto the column for 6 minutes in 100:0 buffer A [water, 0.2% formic acid, and 5% 
DMSO] : buffer B [acetonitrile, 0.2% formic acid, and 5% DMSO] at a flow-rate of 0.250 µL/min. Peptides were 
eluted using the following gradient: an increase to 30% B over 180 min, followed by a 3 min linear gradient from 
30% to 100% B, which was held for 3 minutes. The column was equilibrated with 100% buffer A for an additional 
20 min. Precursor peptide cations were generated from the eluent through the utilization of a nanoESI source.  
Mass spectrometry instrument methods consisted of MS1 survey scans that were used to guide twenty 
subsequent data-dependent MS/MS scans. Mass spectrometry instrument methods consisted of MS1 survey scans 
(1x106 target value; 60,000 resolution; 300 Th – 1500 Th) that were used to guide ten subsequent data-dependent 
MS/MS scans (2 Th isolation window, CAD fragmentation, normalized collision energy of 35; 5x104 target value, 
ion trap). Dynamic exclusion duration was set to 45 s, with a maximum exclusion list of 500 and an exclusion width 
of ±10 ppm around the selected average mass. Maximum injection times were set to 50 ms for all MS1 scans and 75 
ms for MS/MS scans. 
All raw files have been deposited to the CHORUS Project (http://chorusproject.org), an online repository 
for sharing, disseminating, and analyzing mass spectrometry data. The AE-MS experiment contains all 936 raw 
mass spectrometry files from the 6 conditions for each bait, expressed in two different cell lines. The LFQ data 
contains all 30 files collected from the C17orf89 siRNA lines analyzed. All translated raw files can be viewed 
directly in a user’s web browser or downloaded for sharing, disseminating, and analyzing mass spectrometry data.  
Free accounts on Chorus enable users to browse all of the files and download select files or experiments of 









 Data Analysis 
Data was also processed using the MaxQuant software suite (Cox and Mann, 2008; Cox et al., 2011). Searches were 
performed against a target-decoy database (UniProt (human) database, www.uniprot.org, April 4th, 2014, containing 
the 1X FLAG and MFP-GFP-FLAG sequences) using the default settings for high-resolution mass spectra except 
for FTMS MS/MS tolerance which was set to 0.015 Da. A maximum of 2 missed tryptic cleavages were allowed. 
The fixed modification specified was carbamidomethylation of cysteine residues. The variable modification 
specified was oxidation of methionine. Results were filtered to 1% FDR at the unique peptide level and grouped into 
proteins within MaxQuant. Proteins were quantified across all replicates within each bait set using MaxLFQ (Cox et 
al., 2014). Matching between runs was allowed with a retention time window of 1 min.  
 
CompPASS (WD) scoring for protein-protein interactions 
We scored our interactions based on CompPASS scores as previously described with a two key changes (Behrends 
et al., 2010): PPI intensity was measured by averaging the Label free quantification (LFQ) intensity and proteins 
were grouped to avoid punishing interactions observed multiple times within a single complex. 
Briefly the LFQ values from the MaxQuant outputs from all groups of 12 replicates (single bait across cell types and 
carbon source) were combined. WD scores for the interactions were calculated based on the following equations: 
 
Where j corresponds to a prey and i corresponds to a bait. k is the total number of different experimental 
conditions present in the analysis (when all data are used, this number is 78 baits X 2 cell lines X 2 carbon sources = 
312.) fi,j indicates if an interaction between a bait (i) and prey (j) is observed (fi,j=1) or not (fi,j=0.) λ is the reciprocal 
of frequency indicating the specificity of an interaction, and ωj is the coefficient of variation for the strength of an 
interaction (j) across all baits. 
A key variation we added to this analysis is the omission of related proteins from the background dataset to 
improve scoring accuracy for highly interconnected networks. If it is expected that bait A and bait B may be part of 
the same complex, when λ and ωj are calculated for bait A, data from bait B is omitted as not to punish interactions 
from bait A for being present in B (k automatically adjusts for this omission as well). Below is a table of the baits 
we grouped in this way. 
 
Group Name Baits 
COQ (Lohman et al., 2014) ADCK3 
  ADCK4 
  COQ10A 
  COQ10B 
  COQ2 
   COQ3 
  COQ4 
  COQ5 
  COQ6 
  COQ7 
  COQ9 
Complex I (Guarani et al., 2014) NDUFAF4 
  NDUFAF5 
  NDUFS3 
Ketone Body(Shafqat et al., 2013) OXCT1 





After competitive elution with FLAG peptide, the eluate was mixed with protein loading buffer and run on a 10% 
gel for 90 min at 150 V.  
 
Blue Native-PAGE 
NativePAGE Novex 4-16% Bis-Tris protein 10-well gels (LifeTechnologies) were prepared with anode buffer (50 
mM Bis-Tris) and dark cathode buffer (15 mM Bis-Tris/50 mM tricine, 0.02% Serva Blue G-250). Samples were 
mixed with NativePAGE sample buffer (LifeTechnologies, BN2003) to 1x final concentration, and were loaded 
onto gels alongside NativeMARK standard (LifeTechnologies). Gels were run at 150 V for 60 min at 4°C. The dark 
cathode buffer was then replaced with light cathode buffer (0.002% Serva Blue G-250), and the gels were run for 
another 60 min at 250 V. 
For immunoblotting, gels were transferred to PVDF membranes as below (100 V, 1 h, 4°C ). The 
membrane was then incubated in 8% glacial acetic acid in water for 15 min to fix the proteins. After rinsing with 




Protein lysates were prepared in RIPA buffer composed of 150 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris (pH 8.0), 0.4 mM EDTA (pH 8.0), 10% glycerol and a protease inhibitor 
cocktail (Roche Diagnostics), and 20 µg of cleared whole-cell lysate, as determined by BCA assay (Thermo 
Scientific), was separated on a 4-12% Novex NuPAGE Bis-Tris Mini Gel (Invitrogen), transferred to PVDF and 
probed with primary antibodies (listed below).  
 
Primary Antibodies used for Immunoblotting 
Antigen Supplier  Product Number 
β-actin Abcam  ab8224 
C20orf7 (NDUFAF5) Abcam ab192235 
CI subunit 8 kDa  Abcam  ab110245 
ETFA Abcam ab110316 
ETFB Abcam ab73986 
FLAG Sigma F1804 
 NDUFS3  Abcam  ab14711 
OxPhos Antibody Cocktail  (ATP5A1, 
SDHA, UQCRC2, NDUFA9, COXIV) 
Abcam  ab110412 
VDAC  Abcam  ab18988 
 
 
Generation of C17orf89 knockdown cells (For Figure 3) 
Viral particles of the human lentiviral shRNA C17orf89 set (TL320977, OriGene, pGFP-C-shLenti backbone) and 
nonsilencing lentiviral shRNA controls (TR30021, OriGene; shGFP and empty vector in pLKO.1 backbone, The 
Broad Institute) were produced in HEK293 cells. The hairpin sequences for the C17orf89 set are: S1: 
GTTAGAATAAGATGTAACGGAAGCCACGA, S2: GAAGATGTGACATTCCTCGGTGTTAGATC, S3: 
TCCAGCATTGTGTCCGTAA-ACCTGAGTTA, S4: GGACTCTGAGCTTCACACCTGTCTGCTGC. Cell 
transfection was carried out with 5.4 µL 10 mM polyethylenimine (PEI) per µg DNA. HEK293T cells (2 × 106) 
were transfected with 2.5 µg lentiviral shRNA construct together with 1.625 µg psPAX2 and 0.875 µg pMD2.G 
packaging plasmids. Seventy-two hours after transfection, culture medium containing viral particles was passed 
through a 0.45 µm filter, was supplemented with 8 µg/ml polybrene, and was added to HEK293 target cells for 
infection. HEK293 cells were transduced in 6-well plates at 1.5 × 105 cells per well. Transduced HEK293 cells were 
selected in culture medium supplemented with 2 µg/ml puromycin for at least two weeks. Successful knockdown of 
C17orf89 was confirmed by quantitative real-time PCR. 
 
Measurement of Complex I activity. 
Abcam’s Complex I Enzyme Activity Microplate Assay Kit (ab109721) was used to quantify CI activity in 
C17orf89 knock down cell lines. Normalized protein lysate was loaded onto a CI immunocapture plate and 
incubated for 3 hours at room temperature. The plate was washed and then NADH + reaction dye mixture was 
loaded on. The plate was read continuously to measure the rate of NADH turnover. 
 
Measurement of oxygen consumption 
All respiration assays were performed using an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience) with a 4-
port injection system. For initial comparisons of HEK-293 and HepG2 cells, Seahorse 96-well plates were coated 
with poly-D-lysine, and trypsinized HEK-293 or HepG2 cells were plated at 25,000 cells per well on the day prior to 
the assay. After calibration of the assay plate using the XF96 software, cells were loaded into the instrument and 
subjected to a standard mitochondrial stress test protocol. Data analysis was performed using the XF96 software 
(version 1.4.1.4), and the "Level(Direct)Akos" algorithm that is a built-in factor of the software package. 
To test oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in C17orf89 
knockdown cells, two C17orf89 knockdown cell lines (S2 and S3) and one control line transfected with a non-
silencing vector (S5) were plated on poly-D-lysine coated Seahorse 96-well plates at 25,000 cells per well. After a 
24-hr incubation, the growth media were exchanged for XF Assay Medium (Seahorse Biosciences) supplemented 
with 25 mM glucose (Sigma-Aldrich). OCR and ECAR measurements were taken over 3 minute periods following 1 
minute mixing periods. After five initial reads, the cells were treated sequentially with FCCP (Cayman Chemical) to 
a final concentration of 0.1 µM, then rotenone (Sigma-Aldrich) to a final concentration of 1.0 µM, or with 
equivalent volumes of DMSO as a negative control. Three measurements were taken after each addition.  
 
RNAi For CI assembly factor knock down experiments (for Figure 4) 
1 day after seeding, HEK 293 cells were transfected with 10 nM of Dharmacon siGENOME SMARTpools for each 
target or the Non-Targeting siRNA Control Pool #2 using 0.2% of DharmaFECT 1 Transfection Reagent (GE 
Healthcare) based on the manufacturer’s protocol. After 2 days, the cells were passaged, and the next day were 
transfected again with 10 nM siRNA, and after another 2 days were collected for real-time qPCR, immunoblot, and 
mass spectrometry-based proteomic analyses. 
  
Relative Quantification Real Time-qPCR  
Total RNA was purified from cultured cells using the RNeasy Mini Kit (QIAGEN). First- strand cDNA was 
synthesized from purified RNA (500 ng) using the SuperScript III Synthesis System for RT-PCR (Invitrogen). Real 
time-quantitative PCR was performed using SYBR green-based detection (Applied Biosystems) with RPLP0 as the 
endogenous control. Primer sequences are listed below.  
 
Primers used for SYBR Green Real-Time qPCR  
SYBR green primers were designed using the Roche Universal ProbeLibrary Assay Design Center tool or the 
Integrated DNA Technologies (IDT) RealTime qPCR Assay tool. 
 
C17orf89:  
Left: ggccgcctgagtaaggac Right: gacaggtgtgaagctcagagtc 
 
NDUFAF4 (C6orf66): 
Left: gctcccagacacccctcta Right: cagcttttcatctttacgagca 
 
NDUFAF5 (C20orf7): 
Left: gccgaccaaatttgactacc Right: catatacacggtctgcgatcc 
 
NDUFAF6 (C8orf38): 
Left: ctggggcactgaccactac Right: agcagcagggagcataaataa 
 
NDUFS3: 
Left: tgcacagttcaaatctctggtt Right: cgcagagacaacaggttgtaga 
 
RPLP0: 
Left: tctacaaccctgaagtgcttgat Right: caatctgcagacagacactgg 
 
Analysis of CIAF KD lines by mass spectrometry 
Protein samples in urea buffer were reduced in 10 mM TCEP and alkylated with 40 mM chloroacetamide at room 
temperature. Protein was enzymatically digested with sequencing-grade trypsin (Promega, Madison, WI). Digested 
were quenched by acidification with trifluoroacetic acid and immediately desalted using polymeric reversed phase 
solid-phase extraction columns (StrataX, Phenomenex, Torrance, CA).  
All samples were analyzed using a Dionex UPLC system (Thermo Scientific, San Jose, CA) coupled to an Orbitrap 
Elite mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Reverse-phase columns were made in-house by 
packing a fused silica capillary with 1.7 µm diameter, 130 Å pore size Bridged Ethylene Hybrid C18 particles 
(Waters) to a final length of 30 cm. The column was heated to 65°C. Precursor peptide cations were generated from 
the eluent through the utilization of a nanoESI source. Mass spectrometry instrument methods consisted of MS1 
survey scans that were used to guide 20 subsequent data-dependent MS/MS scans (see Supplemental Experimental 
Procedures for further details). 
 
Protein digestion 
Cell pellets were resuspended in 1 mL of 8 M Urea, 40 mM Tris, pH 8, 30 mM sodium chloride, 1 mM calcium 
chloride and 1 tab protease inhibitor (Roche, Indianapolis, IN). Protein was extracted with 9 mL of methanol (1:10 
ratio) and pelleted at 3,500 RPM for 40 minutes. Pellets were air dried for 40 minutes then resuspended in 8 M Urea, 
100 mM Tris. Protein concentration was determined through a BCA assay (Thermo Fisher Scientific). Protein (0.5 
mg) was reduced with 10 mM TCEP and alkylated with 40 mM chloroacetamide at room temperature. Samples 
 were diluted to 1.5 M Urea with 100 mM Tris, pH 8, and then protein was enzymatically digested with sequencing-
grade trypsin in a 1:50 enzyme to protein ratio (Promega, Madison, WI). An additional 1:100 enzyme to protein 
ratio of sequencing-grade trypsin was added in the morning. Digests were quenched by bringing the pH to 2 with 
trifluoroacetic acid and immediately desalted using polymeric reversed phase solid-phase extraction columns 
(StrataX, Phenomenex, Torrance, CA). Peptides were washing with 3 mL of 0.1% TFA and eluted from the 
columns. Prior to LC-MS/MS analysis, peptide concentration was determined using a quantitative colorimetric 
peptide assay (Thermo Fisher Scientific).  
 
LC-MS/MS Analysis 
All samples were analyzed using a Dionex UPLC system (Thermo Scientific, San Jose, CA) coupled to an Orbitrap 
Elite mass spectrometer (Thermo Fisher Scientific, San Jose, CA). Reverse-phase columns were made in-house by 
packing a fused silica capillary (75 µm i.d., 360 µm o.d., with a laser-pulled electrospray tip) with 1.7 µm diameter, 
130 Å pore size Bridged Ethylene Hybrid C18 particles (Waters) to a final length of 30 cm. The column was heated 
to 65°C.  
Samples were loaded onto the column for 6 minutes in 100:0 buffer A [water, 0.2% formic acid, and 5% DMSO] : 
buffer B [acetonitrile, 0.2% formic acid, and 5% DMSO] at a flow-rate of 0.250 µL/min. Peptides were eluted using 
the following gradient: an increase to 30% B over 180 min, followed by a 3 min linear gradient from 30% to 100% 
B, which was held for 3 minutes. The column was equilibrated with 100% buffer A for an additional 20 min. 
Precursor peptide cations were generated from the eluent through the utilization of a nanoESI source.  
Mass spectrometry instrument methods consisted of MS1 survey scans that were used to guide twenty subsequent 
data-dependent MS/MS scans. Mass spectrometry instrument methods consisted of MS1 survey scans (1x106 target 
value; 60,000 resolution; 300 Th – 1500 Th) that were used to guide ten subsequent data-dependent MS/MS scans (2 
Th isolation window, CAD fragmentation, normalized collision energy of 35; 5x104 target value, ion trap). Dynamic 
exclusion duration was set to 45 s, with a maximum exclusion list of 500 and an exclusion width of ±10 ppm around 
the selected average mass. Maximum injection times were set to 50 ms for all MS1 scans and 75 ms for MS/MS 
scans. 
 
Coenzyme Q Quantification 
A frozen pellet of tissue culture cells (isolated from a 20 cm plate at 80–100% confluence) was thawed on ice, 
mixed with glass beads (0.5 mm diameter, 100 µL) and H2O (400 µL, 4 °C), and vortexed (4 x 30 s) to lyse the cells. 
A portion of the cell lysate (containing 2 mg of protein, as determined by a BCA assay) was mixed with H2O (to a 
total volume of 200 µL), spiked with an internal standard (CoQ6, 20 µL, 10 µM), and mixed by vortexing (30 s). 
CHCl3/MeOH (1:1, v/v) (900 µL) was added and vortexed (3 x 30 s). The samples were centrifuged (3,000 g, 3 min, 
4 °C) to complete phase separation. 600 µL of the lower organic phase was transferred to a clean tube. HCl (1 M, 
100 µL, 4 °C) was added to the remaining aqueous phase and vortexed (30 s). CHCl3/MeOH (1:1, v/v) (400 µL) was 
added and vortexed (2 x 30 s). The samples were centrifuged (3,000 g, 3 min, 4 °C) to complete phase separation. 
The lower organic phase was combined with the previous organic extract, and the combined extracts were dried 
under Ar(g). The organic residue was reconstituted in ACN/IPA/H2O (65:30:5, v/v/v) (100 µL) by vortexing (2 x 30 
s). 
Lipids from 10 µL of extract were separated by LC on an Ascentis Express C18 column (150 mm x 2.1 mm 
x 2.7 µm particle size, Supelco, Bellefonte, PA) using an Accela HPLC pump (Thermo Scientific, San Jose, CA) at 
a flow-rate of 0.5 mL/min using a linear gradient. Mobile phase A was 70/30 acetonitrile/water containing 10 mM 
ammonium acetate and 0.025% acetic acid and B was 90/10 isopropanol/acetonitrile containing the same additives. 
Initially the flow was maintained at 50% B for 1.5 min, then ramped to 95% B over 6.5 min, held there for 2 min 
before returning to starting conditions over 1 min, and finally re-equilibrating the column for 2.5 min. The auto 
sampler (HTC PAL, Thermo Scientific) vigorously mixed each sample before injection to ensure homogeneity. 
Quantitation was performed using tandem mass spectrometry by integrating the peak area of the 880.72 à 197.08 Th 
transition of coenzyme Q10 and normalizing to the 591.44 à 197.08 Th transition of the internal standard coenzyme 
Q6 using the Xcalibur software suite (Thermo Scientific, Version 3.0).  MS conditions were as follows: a Q Exactive 
 mass spectrometer (Thermo Scientific, Build 2.5) equipped with a HESI II spray source kept at 350 °C and +4 kV 
was used for detection. The inlet capillary was kept at 350 °C, sheath gas was set to 60 units, and auxiliary gas to 20 
units. Resolving power was set to 35,000, AGC target to 2x105, isolation width to 1 Th, normalized collision energy 
to 27 units, and maximum injection time to 375 ms. 
 
Cell-free expression and purification. 
Plasmid DNA was treated with 0.05 µg/µL proteinase K to remove trace amounts of RNase, purified, and used as 
individual transcription templates with SP6 RNase polymerase. Transcription and translation methods are as 
previously described (Makino et al., 2013). Briefly, transcription reactions included 0.2 mg/mL DNA, 20 mM 
magnesium acetate, 2 mM spermidine trihydrochloride, 10 mM DTT, 80 mM Hepes-KOH, pH 7.8, 4 mM each 
NTP, pH 7.0, 1.6 U/µL SP6 RNA polymerase (Promega), and 1 U/µL RNasin (Promega). Transcriptions were 
incubated for 4 h at 37°C. Nonpurified transcription reactions were used singly or mixed in equal volumes for multi-
protein interaction monitoring and added to wheat germ extract (WEPRO2240; CellFree Sciences) in a standard 
dialysis cup reaction (Makino et al., 2013). Each 25 µL reaction contained 60 O.D. wheat germ extract (6.25 µL), 24 
mM Hepes-KOH, pH 7.8, 100 mM potassium acetate, 6.25 mM magnesium acetate, 0.4 mM spermidine 
trihydrochloride, 4 mM DTT, 1.2 mM ATP, 0.25 mM GTP, 16 mM creatine phosphate, 0.0005% sodium azide, 0.04 
mg/mL creatine kinase, 0.3 mM each amino acid (amino acid mixture adjusted to pH 7.0 with KOH), and 5 µL of 
RNA. Thirty-two-fold excess dialysis buffer was used for each reaction, containing all reaction components except 
for wheat germ extract, creatine kinase, and RNA. After assembly of dialysis cups and 18-h incubation at 23°C , 
duplicate translations (50 µL) of each combination were pooled and centrifuged for 5 min at 20,000 rcf at 10°C. The 
soluble fraction was removed and added to 20 µL of StrepTactin resin equilibrated in 25 mM Hepes, pH 7.8, 150 
mM NaCl, and 1 mM DTT in a 96-well filter plate (HTS Multiscreen; Millipore). The resin with bound protein was 
washed three times with 150 µL of binding buffer. Strep(II)-tagged protein and protein complexes were eluted in 2.5 
mM desthiobiotin in the same buffer. Bound samples were eluted by increasing the imidazole concentration to 500 
mM. Samples of the StrepTactin elutions were loaded without heating on 4-20% Stain-free TGX Criterion gels (Bio-
Rad) and subjected to denaturing SDS/PAGE. Gels were imaged by tryptophan fluorescence using a Bio-Rad Stain 
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